Editor in Chief Cecelia E. Schmalbach, MD, MSc, is joined by author John Pang, MD, and Associate Editor Tristan Tham, MD, to discuss circulating tumor DNA (ctDNA) detection as a new technique to identify minimal residual disease in patients with solid tumors as outlined in the paper “ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment” which published in the August 2024 issue of Otolaryngology–Head and Neck Surgery. They compare ctDNA to the traditional PET to assess best methods.